{"brief_title": "Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis", "brief_summary": "This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).", "condition": ["Rheumatoid Arthritis"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["placebo", "denosumab"], "description": ["placebo subcutaneous injection", "For subcutaneous injection"], "arm_group_label": ["Placebo", "Denosumab 180 mg", "Denosumab 60 mg"], "other_name": ["AMG 162"], "criteria": "Inclusion Criteria: - Diagnosis of RA. - All subjects will be required to have been taking a stable dose of methotrexate. - Active RA at screening defined as greater than or equal to 6 swollen joints. - The presence of erosive disease Exclusion Criteria: - Received any biologic agent (e.g., Enbrel\u00ae, Remicade\u00ae, Humira\u00ae, Kineret\u00ae) or Arava\u00ae within 8 weeks before randomization; past use of these agents is allowed. - Steroid use greater than 15 mg/day. - Scheduled for surgery or joint replacement in the hands, wrists or feet.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Methotrexate", "mesh_term": ["Arthritis", "Arthritis, Rheumatoid", "Denosumab"], "id": "NCT00095498"}